Free shipping on all orders over $ 500


Cat. No. M2272
Suvorexant Structure


Size Price Availability Quantity
10mM*1mL USD 123.3  USD137 In stock
5mg USD 81  USD90 In stock
10mg USD 144  USD160 In stock
50mg USD 540  USD600 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
Biological Activity

Suvorexant (MK-4305) is a dual orexin receptor antagonist currently under clinical investigation as a novel therapy for insomnia. Suvorexant is not currently approved for commercial use, but it has completed three Phase III trials. The recent FDA review showed that Suvorexant (MK-4305) is associated with increased somnolence the next day and users of higher doses had an increased rate of suicidal ideation. Suvorexant works by turning off wakefulness rather than by inducing sleep.

Product Citations
Customer Product Validations & Biological Datas
Source Neurobiology of Aging 2020 Jul. Figure 1. Suvorexant (Abmole Bioscience, USA)
Method oral administration
Cell Lines AD model mice
Concentrations 30 mg/kg
Incubation Time 4 weeks
Results However, compared with 61.8% 2.6% in WT-Veh group, the percentage of correct spontaneous alternation of APP/PS1-Veh group significantly decreased to 48.6% 3.6% (p¼0.001), while suvorexant treatment increased the percentage of APP/PS1 mice to 70.6% 2.4%
Cell Experiment
Cell lines
Preparation method
Incubation time
Animal Experiment
Animal models human OX 2 R expressed in transgenic rats
Formulation 25% hydroxypropyl- β -cyclodextrin
Dosages 0.1 – 2.0 mg/ kg
Administration i.v.
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

Chemical Information
Molecular Weight 450.92
Formula C23H23ClN6O2
CAS Number 1030377-33-3
Purity 99.09%
Solubility DMSO 10 mg/mL
Storage at -20°C

Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist.
Winrow CJ, et al. J Neurogenet. 2011 Mar;25(1-2):52-61. PMID: 21473737.

Related OX Receptor Products
OXA (17-33)

OXA (17-33) is a potent and selective peptide orexin OX1 receptor agonist (EC50 values are 8.29 and 187 nM for OX1 and OX2 receptors respectively).

Orexin 2 Receptor Agonist

Orexin 2 Receptor Agonist (ABM-565520) is a potent and selective Orexin2 receptor agonist with EC50 value of 23 nM.


Lemborexant (E-2006) is an orally active, competitive and reversible dual OX1 and OX2 receptors antagonist, with IC50 values of 6.1 nM and 2.6 nM, respectively.

Orexin A (human, mouse, rat, bovine)

Orexin A (human, mouse, rat, bovine) is a specific, high-affinity agonist for G-protein-coupled receptor OX1R.


MK-1064 is a potent, selective and orally active Orexin OX2 Receptor Antagonist for the research of insomnia.

Abmole Inhibitor Catalog 2017

Keywords: Suvorexant, MK-4305 supplier, OX Receptor, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.